Trevi Therapeutics Inc (TRVI)

NASDAQ
3.700
-0.080(-2.12%)
After Hours
3.880
+0.180(+4.865%)
- Real-time Data
  • Volume:
    381,704
  • Day's Range:
    3.510 - 3.910
  • 52 wk Range:
    0.460 - 4.683

TRVI Overview

Prev. Close
3.78
Day's Range
3.51-3.91
Revenue
-
Open
3.8
52 wk Range
0.46-4.683
EPS
-0.876
Volume
381,704
Market Cap
158.46M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,451,636
P/E Ratio
-4.69
Beta
-
1-Year Change
87.59%
Shares Outstanding
42,770,577
Next Earnings Date
Nov 17, 2022
What is your sentiment on Trevi Therapeutics?
or
Market is currently closed. Voting is open during market hours.

Trevi Therapeutics Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Trevi Therapeutics Inc Analysis

Trevi Therapeutics Inc Company Profile

Trevi Therapeutics Inc Company Profile

Employees
24

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellNeutralBuy
Technical IndicatorsStrong SellStrong SellStrong SellSellStrong Buy
SummaryStrong SellStrong SellStrong SellNeutralStrong Buy
  • Added long at $0,65
    0
    • sophia ppayan
      0
      • This one is coming now.
        0